Abbott India’s story in the country predates independence itself. Incorporated on August 22, 1944 as Boots Pure Drug Company (India) Ltd, the company has operated under three different names across eight decades, each reflecting a chapter in the consolidation of global healthcare. Today, as the Indian subsidiary of Abbott Laboratories, it is a $750 million business with more than 400 trusted brands spanning pharmaceuticals, diagnostics, nutrition, and medical devices, one of the most diversified healthcare companies operating in India.
The company that is today known as Abbott India has existed under three names, each marking a shift in global pharmaceutical ownership. It was incorporated in 1944 as Boots Pure Drug Company (India) Ltd, a subsidiary of the British pharmaceutical firm Boots. In 1995, following the acquisition of Boots’ pharmaceutical division by the German company Knoll, it became Knoll Pharmaceuticals Ltd. Then in 2001, when Abbott Laboratories acquired Knoll, the Indian entity was renamed Abbott India Ltd in 2002.
This lineage matters because it means Abbott India did not arrive in the country as a greenfield operation. It inherited decades of established physician relationships, brand equity, and manufacturing infrastructure built under its predecessor names. The Boots and Knoll eras created a foundation of trust with Indian healthcare professionals that Abbott then expanded upon with its global resources, R&D pipeline, and diversified product portfolio.
Headquartered in Mumbai, Abbott India is one of the highest market-capitalisation pharmaceutical companies listed on Indian stock exchanges. Its FY25 revenue of INR 6,409 crore (approximately $750 million) represents 11.6% growth over the prior year, a pace that reflects both the strength of its existing brands and successful new product introductions.
What distinguishes Abbott India from most Indian pharmaceutical companies is the breadth of its healthcare portfolio. While the majority of domestic pharma companies compete exclusively in branded generics and API manufacturing, Abbott India operates across four distinct business segments: pharmaceuticals, diagnostics, nutrition, and medical devices. This diversification is a direct consequence of its parent company’s global structure.
In diabetes care, Abbott has established market leadership in India through the FreeStyle Libre continuous glucose monitoring system, a device that has transformed how millions of diabetic patients manage their condition by eliminating the need for routine finger-prick blood tests. The technology represents a category of innovation that Indian pharmaceutical companies, focused primarily on molecule-based therapies, have not traditionally pursued.
In cardiac devices, the Aveir DR leadless pacemaker represents Abbott’s position at the frontier of implantable medical technology. The nutrition business, anchored by established brands trusted by Indian families for decades, provides a stable revenue base with consumer-goods-like recurring demand. And the diagnostics division supplies laboratory instruments and point-of-care testing equipment to hospitals across the country.
This multi-segment model means Abbott India is not solely dependent on the pricing dynamics and regulatory environment of the pharmaceutical market. When drug price controls tighten, the devices and nutrition businesses provide ballast. When hospital capital expenditure cycles favour new equipment, the diagnostics division benefits. It is a structurally different business from a pure-play pharma company.
Abbott India operates three manufacturing plants across the country: in Baddi (Himachal Pradesh), Goa, and Jhagadia (Gujarat). The geographic spread is deliberate, each location offers distinct advantages in terms of regulatory incentives, proximity to raw material suppliers, and access to skilled labour pools.
The Baddi facility in Himachal Pradesh is located in one of India’s most established pharmaceutical manufacturing clusters, a region that attracted significant investment after the Indian government offered tax incentives for industrial development in the state. The Goa plant operates in a smaller but well-regarded manufacturing ecosystem, while the Jhagadia facility in Gujarat places Abbott within the country’s largest pharmaceutical manufacturing corridor.
With approximately 7,600 employees across the organisation, Abbott India maintains the manufacturing, quality assurance, and commercial infrastructure required to support more than 400 brands across its diversified portfolio. The scale of the workforce reflects the company’s breadth: it takes a different kind of organisation to manage pharmaceutical field forces, device sales teams, nutrition distribution networks, and diagnostic equipment service engineers simultaneously.
As a subsidiary of Abbott Laboratories, Abbott India has access to resources that purely domestic pharmaceutical companies cannot easily replicate. The parent company’s global R&D pipeline provides a steady flow of new molecules, devices, and diagnostic platforms that can be introduced into the Indian market without the Indian subsidiary bearing the full cost of development. When Abbott Laboratories invests billions in developing a new cardiac device or glucose monitoring system, the Indian subsidiary can bring that innovation to one of the world’s largest patient populations.
This advantage extends beyond product development. Abbott’s global quality systems, manufacturing best practices, and regulatory expertise set a baseline standard that the Indian operations inherit. Training programmes, standard operating procedures, and quality benchmarks developed across Abbott’s global network of facilities are deployed in India, creating a level of operational consistency that is difficult to build from scratch.
The MNC model also carries constraints. Abbott India’s strategic direction is ultimately set by its parent company, and the Indian operation must balance local market needs with global corporate priorities. But for Indian patients and healthcare professionals, the practical effect is access to a portfolio of pharmaceutical, diagnostic, nutritional, and device products backed by the full resources of one of the world’s largest healthcare companies, delivered through eight decades of established local presence.
Sources: Abbott India Limited Annual Reports and investor presentations. Abbott Laboratories corporate filings and product disclosures. Indian stock exchange filings (BSE/NSE).